Open AccessTenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations
Author(s) -
Won Hyeok Choe,
Ki-Jeong Kim,
So Young Lee,
Yu Min Choi,
So Young Kwon,
Jeong Han Kim,
Bum Joon Kim
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i33.4985
Subject(s) - entecavir , medicine , genotype , gastroenterology , hepatitis b virus , virology , hepatitis b , virus , biology , lamivudine , gene , genetics
Hepatitis B virus (HBV) DNA polymerase mutations usually occur to long term use of nucleos(t)ide analogues (NAs), but they can occur spontaneously in treatment-naïve chronic hepatitis B (CHB) patients. The naturally occurring HBV DNA polymerase mutations might complicate antiviral therapy with NAs, leading to the generation of drug-resistant viral mutants and disease progression. The most common substitutions are known to be YMDD-motif mutations, but their prevalence and the influence on antiviral therapy is unclear.